POM-V Prescription Required Companion Animal

Medrone V Tablets 2 mg

Active ingredient: Methylprednisolone

Form

Tablet

Species

Cats Dogs

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5227

What it's used for

For the treatment of, or as part of a therapeutic regime for inflammatory and allergic conditions such as: allergic or non-specific inflammatory dermal con...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Methylprednisolone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Medrone V Tablets 2 mg — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the treatment of, or as part of a therapeutic regime for inflammatory and
allergic conditions such as: allergic or non-specific inflammatory dermal
conditions, musculo-skeletal conditions, ocular/otic inflammatory conditions and
other inflammatory/allergic conditions that are likely to respond to corticosteroid
therapy e.g. immune-mediated disorders.

The dosage needed may vary according to individual clinical circumstances
such as severity of the condition to be treated, the anticipated duration of
therapy and even to take into account the individuals case history.
The following dosage recommendations are therefore initial guidelines and may
require modification in the light of individual clinical circumstances.
BodyweightAverage total daily dosage
1-5 kg1 mg5-9 kg2 mg9-18 kg2 to 4 mg18-36 kg4 to 8 mg
The initial daily dose should be given in two equally divided doses.
In order to control clinical signs of certain autoimmune disorders e.g.
Pemphigus vulgaris, the initial dosage may have to be higher than that
suggested above.
As soon as a satisfactory clinical response is achieved, the daily dose should be
reduced gradually, either to termination of treatment in the case of acute
conditions or to the minimal effective maintenance dose level in the case of
chronic conditions.
The veterinary surgeon may, at his/her discretion, use alternate day therapy in
order to maintain minimal effective therapy of chronic conditions: dogs should
be treated on every alternate morning and cats on every alternate evening.

Systemic corticosteroid therapy is generally contra-indicated in patients with
renal disease and diabetes mellitus.

Anti-inflammatory corticosteroids, such as methylprednisolone, are known to
exert a wide range of side-effects. Whilst single high doses are generally well
tolerated, they may induce severe side-effects in long term use and when esters
possessing a long duration of action are administered. Dosage in medium to
long term use should therefore generally be kept to the minimum necessary to
control clinical signs.
Steroids themselves, during treatment, may cause Cushingoid symptoms
involving significant alteration of fat, carbohydrate, protein and mineral
metabolism, e.g. redistribution of body fat, muscle weakness and wastage and
osteoporosis may result. During therapy, effective doses suppress the
Hypothalamo-Pituitary-Adrenal axis.
Following cessation of treatment, signs of adrenal insufficiency extending to
adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations. Consideration should therefore be given to
means of minimising problems of adrenal insufficiency following the withdrawal
of treatment, e.g. dosing to coincide with the time of the endogenous cortisol
peak (i.e. in the morning with regard to dogs and the evening with regard to
cats) and a gradual reduction of dosage (for further discussion see standard
texts).
Systemically administered corticosteroids may cause polyuria, polydipsia and
polyphagia, particularly during the early stages of therapy. Some
corticosteroids may cause sodium and water retention and hypokalaemia in
longer term use.
Systemic corticosteroids have caused deposition of calcium in the skin
(calcinosis cutis).
Corticosteroids may delay wound healing and the immunosuppressant actions
may weaken resistance to or exacerbate existing infections. In the presence of
bacterial infection, anti-bacterial drug cover is usually required when steroids
are used. In the presence of viral infections, steroids may worsen or hasten the
progress of the disease.
Gastrointestinal ulceration has been reported in animals treated with
corticosteroids and g.i.t. ulceration may be exacerbated by steroids in patients
given non-steroidal anti-inflammatory drugs and in animals with spinal cord
trauma. Steroids may cause enlargement of the liver (hepatomegaly) with
increased serum hepatic enzymes.
During a course of treatment the situation should be reviewed frequently by
close veterinary supervision.

Revised: December 2025
MA split from NI Expiry following AN: 02959/2025

None.

(i) Special precautions for use in animals
See under 4.6.

Revised: December 2025
MA split from NI Expiry following AN: 02959/2025
(ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Wash hands after use. In the event of accidental ingestion, seek medical
advice and show the doctor what has been taken. Veterinary practitioners
should use child resistant closures when dispensing this product.

Concurrent administration of barbiturates, phenylbutazone, phenytoin or
rifampicin may enhance the metabolism and reduce the effect of corticosteroids.
Response to anticoagulants may also be reduced by corticosteroids.

Do not store above 25
o
C. Store in tightly closed original container. Protect from
light.

Not applicable.

Revised: December 2025
MA split from NI Expiry following AN: 02959/2025
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.